article thumbnail

STAT+: Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show

STAT

The FDA’s months-long internal examination of the LBP yielded a series of documents seen by STAT, including a lengthy review, completed in August 2019, of the Mount Sinai study. The review, which lists consultations with 16 different FDA officials, was scathing.

article thumbnail

Juul’s internal playbook opens a rare window into influence in Washington

STAT

WASHINGTON — A new trove of internal emails and other documents from the e-cigarette maker Juul reveals the company’s extensive behind-the-scenes efforts to promote its interests in Washington — a rare insight into the otherwise opaque methods corporations use to influence the government.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NIH spending for drugs approved 2010-2019 lower than industry spending, study finds

European Pharmaceutical Review

New research published in JAMA Health Forum has documented that the US National Institutes of Health (NIH) spent $8.1 billion for phased clinical trials of US Food and Drug Administration (FDA)-approved drugs between 2010-2019. This was ~10 percent of reported industry spending. billion (3.3

article thumbnail

STAT+: As regulators play catch up with AI, tech startups say uncertainty is slowing them down

STAT

health care market , AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. As they race for a slice of the $4 trillion U.S. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

article thumbnail

STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more

STAT

Merdad Parsey, who joined Gilead in 2019, will stay in his post until the first quarter of next year as the company looks for a successor. Gilead  Gilead has faced multiple setbacks in its attempt to move away from its stronghold in virology and into other areas like cancer. The EC says she did not keep the messages.

article thumbnail

STAT+: Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug

STAT

In their filing , which was made in 2019, the groups argued that “unlawful conduct” carried out by Gilead had hurt the public interest, because its prices led the government to ration the Sovaldi medication.

article thumbnail

Revised pharmacovigilance guidance for human vaccines open for public consultation

Express Pharma

This update aims to align the guidance with the New Drugs and Clinical Trials Rules, 2019, and has been developed in collaboration with the AEFI Secretariat and IPC-PVPI. The statement further adds that the feedback, along with valid justifications, should be emailed to psur.drugs@cdsco.nic.in.